Milatuzumab
Milatuzumab is a monoclonal antibody that is primarily researched and developed for the treatment of various cancers, including multiple myeloma and non-Hodgkin lymphoma. This therapeutic agent targets the CD74 antigen on the surface of B cells, which is an important molecule involved in the immune system's antigen presentation process.
Development and Mechanism[edit | edit source]
Milatuzumab was developed as a humanized monoclonal antibody. Humanized antibodies are engineered from non-human antibodies to reduce immunogenicity and increase efficacy in human patients. The primary mechanism of action of milatuzumab involves binding to the CD74 antigen on B cells. CD74 is involved in the immune system's antigen processing and is overexpressed in certain types of cancer cells. By targeting CD74, milatuzumab can induce direct cytotoxic effects or recruit the immune system to attack the cancer cells.
Clinical Trials[edit | edit source]
Milatuzumab has been evaluated in several clinical trials, particularly focusing on its efficacy and safety in treating conditions like multiple myeloma and non-Hodgkin lymphoma. These trials assess various aspects such as optimal dosing, response rates, and potential side effects. The outcomes of these trials are crucial for determining the future clinical use of milatuzumab in oncology.
Potential Applications[edit | edit source]
Beyond its primary applications in treating hematological malignancies, research is ongoing to explore the use of milatuzumab in other therapeutic areas. This includes potential roles in treating autoimmune diseases due to its mechanism of action involving B cells, which are also key players in many autoimmune conditions.
Challenges and Future Directions[edit | edit source]
While milatuzumab shows promise, there are several challenges to its widespread adoption. These include understanding the full spectrum of its immunological effects, managing any adverse reactions, and establishing clear therapeutic protocols. Future research will likely focus on optimizing its clinical efficacy and exploring combination therapies with other anticancer agents to enhance treatment outcomes.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
